Clinical trials: Glaucoma and Ocular Hypertension
Open-Angle Glaucoma, Ocular Hypertension
A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study was to assess the effects of total volume and total dose on the safety and intraocular pressure-lowering efficacy of Anecortave Acetate Suspension (3 mg and 48 mg) in 0.5 mL and 0.8 mL volumes when…
- Trial name
- NCT00788541
- Testing
- Anecortave Acetate Sterile Suspension, 6 mg/mL, Anecortave Acetate Sterile Suspension, 3.75 mg/mL, Anecortave Acetate Sterile Suspension, 96 mg/mL
- Where
- United States
- Volunteers
- 197 people
- Sponsor
- Alcon Research
Glaucoma, Ocular Hypertension
Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy
The purpose of this study was to evaluate the safety and efficacy of adding AZARGA® as a single agent to prostaglandin monotherapy in patients with either ocular hypertension or primary open-angle glaucoma.
- Trial name
- NCT01263444
- Testing
- Brinzolamide 1% / timolol 0.5% Fixed Combination, Habitual prostaglandin monotherapy
- Volunteers
- 47 people
- Sponsor
- Alcon Research
Glaucoma
Circular Cyclocoagulation Using HIFU With EYEOP1 Device in Glaucoma Patients
The aim of the study is to evaluate the effectiveness and the safety of the cyclocoagulation using HIFU in glaucoma patients
- Trial name
- NCT01791673
- Testing
- Ultrasound glaucoma treatment
- Where
- 5 sites in France
- Volunteers
- 30 people
- Sponsor
- EyeTechCare
Glaucoma
Evaluating the Efficacy and Safety of Xalost S in Glaucoma Patients.
In patients with Glaucoma, Xalost S or Xalatan or Taflotan-S are administered for 12 weeks. After 12 weeks, among them, Xalatan administration group are switched to Xalost S or Taflotan-S. Extension study period is 8 weeks.
- Trial name
- NCT04164459
- Testing
- Xalost S, Xalatan, Taflotan-S
- Where
- South Korea
- Volunteers
- 144 people
- Sponsor
- Taejoon Pharmaceutical Co., Ltd.
Elevated Intraocular Pressure
A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)
Double-masked, randomized, multi-center, placebo-controlled parallel-comparison of AR-12286.
- Trial name
- NCT00902200
- Testing
- AR-12286, AR-12286 vehicle
- Where
- 8 sites in United States
- Volunteers
- 89 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America
The purpose of this study was to assess the efficacy and tolerability of changing to AZARGA® from prior COMBIGAN® pharmacotherapy in participants with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01518244
- Testing
- Brinzolamide/timolol maleate fixed combination
- Volunteers
- 50 people
- Sponsor
- Alcon Research
Primary Open Angle Glaucoma
CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation
This study is intented to evaluate the safety, tolerability and preliminary efficacy of CRISPR/Cas9 Instantaneous Gene Editing Therapy (BD113 virus-like particle, also BD113vLVP) in patients with primary open-angle glaucoma…
- Trial name
- NCT06465537
- Testing
- BD113vVLP
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai BDgene Co., Ltd.
Primary Open Angle Glaucoma
Safety and Performance of Miami InnFocus Drainage Implant (MIDI Arrow) Glaucoma Drainage Implant
To assess the safety and performance of the MIDI Arrow in patients suffering from glaucoma that is inadequately controlled on maximum tolerated medical therapy with intraocular pressure ≥ 18 mm Hg and ≤ 40 mm Hg
- Trial name
- NCT01563237
- Testing
- MIDI Arrow
- Where
- France
- Volunteers
- 69 people
- Sponsor
- InnFocus Inc.
Ocular Hypertension, Primary Open-Angle Glaucoma
Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
This study has 2 parts. Part 1 will evaluate the safety and IOP effects of 6 formulations of AGN-210961 ophthalmic solution in the study eye and bimatoprost ophthalmic solution 0.03% in the fellow eye for 7 consecutive days.
- Trial name
- NCT01110499
- Testing
- AGN-210961 Formulation 1, AGN-210961 Formulation 2, AGN-210961 Formulation 3
- Where
- United States
- Volunteers
- 163 people
- Sponsor
- Allergan
Cataract, Ocular Hypertension
Evaluation of the Safety and Effectiveness of the Bimatoprost Implant System / IOL Combination in Patients With Ocular Hypertension or Mild to Moderate Open-angle Glaucoma
The goal of this clinical trial is to learn if the SpyGlass Pharma Bimatoprost Implant System / IOL Combination works to treat cataracts and either ocular hypertension or glaucoma.
- Conditions
- Cataract, Ocular Hypertension, Glaucoma
- Trial name
- NCT07154797
- Testing
- Bimatoprost Implant System / IOL Combination
- Where
- Honduras
- Volunteers
- 24 people
- Sponsor
- SpyGlass Pharma, Inc.
Glaucoma
Ocular Hypotensive Efficacy of AR-102
A double-masked, randomized, vehicle-controlled, dose-response study assessing the safety and ocular hypotensive efficacy of AR-102 in subjects with elevated intraocular pressure.
- Trial name
- NCT00523250
- Testing
- AR-102 0.003% Ophthalmic Solution, AR-102 0.005% Ophthalmic Solution, AR-102 0.01% Ophthalmic Solution
- Where
- 8 sites in United States
- Volunteers
- 82 people
- Sponsor
- Aerie Pharmaceuticals
Open Angle Glaucoma (OAG)
Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma
A Prospective, Multicenter, Single-Arm, Open-Label Clinical Trial
- Trial name
- NCT07220876
- Testing
- VisiPlate Glaucoma Implant
- Where
- 14 sites in United States, South Africa
- Volunteers
- 165 people
- Sponsor
- Avisi Technologies Inc.
Glaucoma, Open-Angle
Study of an Interposition Supraciliary Implant in Patients With Open Angle Glaucoma
The purpose of this study is to prolong observational follow-up up to 36 months of patients already implanted with a novel interposition supraciliary implant.
- Trial name
- SAFARI FU (NCT05159817)
- Where
- Armenia
- Volunteers
- 19 people
- Sponsor
- Ciliatech
Open Angle Glaucoma, Primary Open Angle Glaucoma
Safety and Effectiveness of the Hydrus Microstent
The purpose of this study is to assess the safety and effectiveness of the Hydrus Microstent for lowering intraocular pressure (IOP) in pseudophakic patients with open-angle glaucoma for whom IOP is not sufficiently controlled on…
- Conditions
- Open Angle Glaucoma, Primary Open Angle Glaucoma, Pseudoexfoliation Glaucoma, Pigmentary Glaucoma
- Trial name
- FRONTIER (NCT05198297)
- Testing
- Hydrus Microstent, Ophthalmic surgery
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- Alcon Research
Healthy Eyes, Eye Diseases
Triton Agreement and Precision Study
To Compare the agreement and precision between the Topcon DRI OCT Triton and the 3D OCT-1 Maestro with RDB.
- Trial name
- NCT03080714
- Testing
- Topcon DRI OCT Triton (plus), 3D OCT-1 Maestro
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Topcon Medical Systems, Inc.
Primary Open Angle Glaucoma, Glaucoma, Open Angle, Pseudo-exfoliative
Safety and Efficacy Trial to Evaluate the Hydrus(TM) Implant in Subjects Undergoing Cataract Surgery.
The objective of this study is to demonstrate the ability of the Hydrus Implant to lower intraocular pressure in glaucoma patients undergoing cataract surgery.
- Conditions
- Primary Open Angle Glaucoma, Glaucoma, Open Angle, Pseudo-exfoliative, Cataract Unilateral Pending Extraction
- Trial name
- Hydrus II (NCT01818115)
- Testing
- Hydrus Implant, IOL placement
- Where
- 7 sites in Germany, Italy and 2 more
- Volunteers
- 100 people
- Sponsor
- Ivantis, Inc.
Glaucoma, Neovascular
Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients
To assess the efficacy and safety of the administration of aflibercept by intravitreal injection in comparison to sham to control intraocular pressure in patients with neovascular glaucoma.
- Trial name
- VEGA (NCT02396316)
- Testing
- Aflibercept (Eylea, BAY 86-5321)
- Where
- 19 sites in Japan
- Volunteers
- 54 people
- Sponsor
- Bayer
Open-angle Glaucoma, Ocular Hypertension
Phase 4 Study Comparing IOP Lowering in OAG or OH in Caucasian or Japanese Subjects C-02-32
The purpose of this study is to evaluate safety and efficacy of two different IOP lowering medications after six weeks of treatment in Caucasian and Japanese subjects.
- Trial name
- NCT00047606
- Testing
- IOP Lowering Medications
- Volunteers
- 84 people
- Sponsor
- Alcon Research
Open-Angle Glaucoma
Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma
Glaucoma is the second most common cause of blindness in the world, second only to cataracts. This study will assess how safe and effective a glaucoma gel stent is when implanted using the ab externo approach.
- Trial name
- NCT05411198
- Testing
- XEN45 (Glaucoma Gel Stent)
- Where
- 25 sites in United States, Australia
- Volunteers
- 74 people
- Sponsor
- AbbVie
Glaucoma, Ocular Hypertension
Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
This study will evaluate the safety and efficacy of bimatoprost/timolol formulation A ophthalmic solution with Ganfort® (bimatoprost 0.03%/timolol 0.5% ophthalmic solution) once daily for 12 weeks in patients with glaucoma or…
- Trial name
- NCT01177098
- Testing
- bimatoprost /timolol formulation A fixed combination ophthalmic solution, bimatoprost/timolol fixed combination ophthalmic solution
- Where
- 9 sites in United States, Australia and 7 more
- Volunteers
- 561 people
- Sponsor
- Allergan